Savant Capital
ADPT icon

Savant Capital’s Adaptive Biotechnologies ADPT Stock Holding History

Savant Capital’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$455K Buy
+15,751
New +$387K ﹤0.01% 1618
2026
Q2 		– Sell
-16,651
Closed -$231K – 1840
2026
Q1 		$231K Buy
16,651
+154
+0.9% +$2.45K ﹤0.01% 1322
2025
Q4 		$268K Buy
16,497
+4
+0% +$65 ﹤0.01% 1124
2025
Q3 		$247K Hold
16,493
– – ﹤0.01% 1135
2025
Q2 		$192K Hold
16,493
– – ﹤0.01% 1155
2025
Q1 		$123K Sell
16,493
-17,728
-52% -$136K ﹤0.01% 1031
2024
Q4 		$205K Buy
34,221
+1
+0% +$6 ﹤0.01% 1314
2024
Q3 		$175K Hold
34,220
– – ﹤0.01% 1296
2024
Q2 		$124K Buy
34,220
+17,594
+106% +$55.8K ﹤0.01% 1187
2024
Q1 		$53.4K Buy
16,626
+133
+0.8% +$515 ﹤0.01% 1095
2023
Q4 		$80.8K Sell
16,493
-1,500
-8% -$6.84K ﹤0.01% 829
2023
Q3 		$98.1K Buy
+17,993
New +$119K ﹤0.01% 784

Other funds holding ADPT

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 42.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Savant Capital's ADPT Position: Q3 2026 in Review

Savant Capital opened a new position in Adaptive Biotechnologies (ADPT) in Q3 2026: 15,751 shares worth $455K. The stake represents ﹤0.01% of the portfolio and ranks #1618 among its holdings. This is a return to the name: Savant Capital previously reported a position in ADPT as recently as Q1 2026.

Savant Capital first reported a position in ADPT in Q3 2023 and has held it in 12 quarters since. 190 funds tracked by Wall St. Rank hold ADPT as of Q3 2026.

  • Savant Capital held 15,751 shares of Adaptive Biotechnologies worth $455K as of Q3 2026.
  • Adaptive Biotechnologies was a new Savant Capital position in Q3 2026.
  • Adaptive Biotechnologies made up ﹤0.01% of Savant Capital's portfolio in Q3 2026, its #1618 holding.
  • Savant Capital first reported a position in Adaptive Biotechnologies in Q3 2023 and has held it in 12 quarters since.
  • 190 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q3 2026.

Based on Savant Capital's 13F filing for Q3 2026, filed 6 Nov 2026.